Date published: 2025-12-19

1-800-457-3801

SCBT Portrait Logo
Seach Input

VSV-G Inhibitors

VSV-G inhibitors constitute a distinctive class of chemical compounds that primarily target the vesicular stomatitis virus glycoprotein (VSV-G) and modulate its biological activity. The VSV-G glycoprotein is an integral component of the vesicular stomatitis virus, a member of the Rhabdoviridae family, which encompasses a broad range of enveloped viruses. The viral glycoprotein plays a pivotal role in mediating viral entry into host cells by facilitating the fusion of the viral envelope with the host cell membrane. VSV-G inhibitors are designed to interfere with this crucial process, thereby impeding the virus's ability to initiate infection and propagate within the host. Structurally, VSV-G inhibitors exhibit remarkable diversity, as they can be synthesized as small organic molecules or even be found innatural sources. Their mechanism of action involves interaction with specific regions of the VSV-G glycoprotein, which may hinder its proper folding, oligomerization, or engagement with cellular receptors. Consequently, the inhibitors disrupt the fusion process between the viral envelope and the host cell membrane, impeding the internalization of the viral genetic material into the host cell and subsequently curbing the progression of viral infection. The development of VSV-G inhibitors is a result of extensive research into the molecular interactions between the virus and its target cells. This class of compounds showcases the intricate nature of the interplay between viral components and host cell machinery, highlighting the ability for novel strategies to counteract viral infections.

In conclusion, VSV-G inhibitors constitute a distinctive class of chemical entities that intricately disrupt the vesicular stomatitis virus glycoprotein's function, impeding the virus's entry into host cells. These compounds represent the culmination of research into the molecular mechanisms of viral infection and hold promise as tools for understanding viral entry processes at a fundamental level. The diversity of their structural composition underscores the intricate nature of the virus-host interaction and presents avenues for the development of antiviral strategies.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Brefeldin A

20350-15-6sc-200861C
sc-200861
sc-200861A
sc-200861B
1 mg
5 mg
25 mg
100 mg
$30.00
$52.00
$122.00
$367.00
25
(3)

Inhibits protein transport between ER and Golgi by disrupting COPI

Monensin A

17090-79-8sc-362032
sc-362032A
5 mg
25 mg
$152.00
$515.00
(1)

Disrupts intracellular trafficking by altering ion gradients

Methyl-β-cyclodextrin

128446-36-6sc-215379A
sc-215379
sc-215379C
sc-215379B
100 mg
1 g
10 g
5 g
$25.00
$65.00
$170.00
$110.00
19
(1)

Sequesters cholesterol, affecting lipid rafts and membrane fusion

Chlorpromazine

50-53-3sc-357313
sc-357313A
5 g
25 g
$60.00
$108.00
21
(1)

Alters membrane fluidity and inhibits endocytosis

1-Adamantylamine

768-94-5sc-251475
sc-251475A
1 g
25 g
$38.00
$144.00
(0)

Interferes with viral uncoating and membrane fusion

Arbidol Hydrochloride

131707-23-8sc-210834
10 mg
$204.00
(1)

Blocks viral entry by interacting with viral envelope protein

Nitazoxanide

55981-09-4sc-212397
10 mg
$122.00
1
(1)

Inhibits viral replication and potentially entry

Nelfinavir

159989-64-7sc-507314
10 mg
$168.00
(0)

Inhibits protease activity involved in viral replication

Lovastatin

75330-75-5sc-200850
sc-200850A
sc-200850B
5 mg
25 mg
100 mg
$28.00
$88.00
$332.00
12
(1)

Inhibits cholesterol synthesis, affecting lipid rafts

Toremifene

89778-26-7sc-205868
sc-205868A
500 mg
1 g
$85.00
$129.00
1
(1)

Blocks viral entry by affecting fusion of viral envelope with host cell membrane